Grail CEO Joshua Ofman sells $2.74m in company stock
On October 15, 2026, GRAIL, Inc. CEO Joshua J. Ofman sold 20,000 shares of the company's common stock, totaling approximately $2,736,944. The sales were made in multiple transactions at prices ranging from $132.67 to $139.17 per share, executed according to a Rule 10b5-1 trading plan adopted on December 2, 2025. Following the sale, Ofman still owns 342,271 shares of GRAIL Inc. common stock.
However, GRAIL's stock has declined by around 16% in the past week, closing at $117.81, which is lower than the sale prices. The company is currently considered overvalued by InvestingPro. The FDA Advisory Committee recently approved GRAIL's Galleri multi-cancer early detection test, with a unanimous 10-0 vote on safety and a 6-4 vote on effectiveness.
This positive outcome has led several financial firms to adjust their outlooks on GRAIL. TD Cowen increased its price target to $180, Canaccord Genuity raised it to $150, and Mizuho set it to $100, all emphasizing the test's safety and effectiveness. The FDA staff's lack of major concerns has boosted investor confidence.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
